Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01656889 |
Recruitment Status
:
Completed
First Posted
: August 3, 2012
Results First Posted
: March 14, 2016
Last Update Posted
: March 14, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA).
This research is being done to compare the efficacy of HP802-247 plus compression therapy against Vehicle plus compression therapy in achieving complete wound closure over the 12-week treatment period. Vehicle looks the same as HP802-247 but contains no cells.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Venous Leg Ulcers | Biological: HP-802-247 Biological: Vehicle | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 447 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers |
Study Start Date : | August 2012 |
Actual Primary Completion Date : | December 2014 |
Actual Study Completion Date : | December 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: HP802-247
HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
|
Biological: HP-802-247
HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
|
Placebo Comparator: Vehicle
Vehicle Control (fibrinogen solution & thrombin solution without cells)
|
Biological: Vehicle
(fibrinogen solution & thrombin solution without cells)
|
- Compare the Treatment Groups for the Proportion of Subjects With Complete Wound Closure Over the 12-Week Treatment Period From Baseline [ Time Frame: 12 Weeks ]For each treatment group the area of each subject's target ulcer was measured on a weekly basis, for up to 12 weeks, using a laser-based wound imaging system in conjunction with software to measure area. Following initial closure subjects returned for four weekly visits to confirm wound closure. Wounds that remained closed for four weeks were classified as confirmed closures; if a wound opened at any of the 4 visits it was not considered to have closed. For subjects who dropped from the study, their remaining visit values were imputed using LOCF; wound status of closed was not imputed.
- Compare the Efficacy of the Treatment Groups in Achieving Complete Wound Closure, Based on Time in Days to Closure Over the 12-Week Treatment Period From Baseline. [ Time Frame: 12 Weeks ]This key secondary outcome was based on a Cox Proportional Hazard Analysis and a Kaplan-Meier survival analysis.
- Compare the Treatment Groups for the Percentage of Closed Ulcers at Each Visit of the 12-Week Treatment Period From Baseline [ Time Frame: Weekly, over the 12 week treatment period, or until wound closure, which ever occurred first ]Treatment groups were compared for the proportion of wounds closed at each weekly visit. For subjects who dropped from the study, their remaining visit values were imputed using LOCF.
- Number of Subjects With Durable Wound Healing Over the 3 Months Following Complete Wound Closure [ Time Frame: Target ulcer status observed at two and three months following initial ulcer closure. ]Subjects who completed the treatment period with confirmed wound closure were followed in the post-treatment period for a further two months to determine their closed wound status (remained closed/reopened), giving a measure of persistence of wound closure following completion of treatment.
- Change in Pain Associated With the Target Leg at Each of the 12 Double Blind Treatment Weeks [ Time Frame: Weekly, over the 12 week treatment period, baseline ]Target leg pain were measured using a Visual Analog Scale [Range: 0mm - 100mm]. Subjects marked their pain level on a 100 mm horizontal line, with a short vertical line across the scale, 0 denoting no pain and 100mm the maximum pain.
- Change in Target Ulcer Pain [ Time Frame: Weekly, over 12 week treament period, baseline ]Target ulcer pain were measured using a Visual Analog Scale [Range: 0mm - 100mm]. Subjects marked their pain level on a 100 mm horizontal line, with a short vertical line across the scale, 0 denoting no pain and 100mm the maximum pain.
- Compare the Efficacy of the Treatment Groups in Achieving Complete Wound Closure, Based on the Median Time (in Days) to Closure Over the 12-Week Treatment Period From Baseline. [ Time Frame: 12 weeks ]This key secondary outcome was based on a Kaplan-Meier survival analysis.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Provide informed consent.
- Age ≥ 18 years and of either sex.
- Willing to comply with protocol instructions, including allowing all study assessments.
- Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area ≥ 2.0 cm2 and ≤ 12.0 cm2
- Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.
- Arterial supply adequacy confirmed
- Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone.
- Target ulcer duration ≥ 6 weeks but ≤ 104 weeks (24 months).
- Acceptable state of health and nutrition
Exclusion Criteria:
- History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B.
- Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication.
- Therapy with another investigational agent within thirty (30) days of Screening, or during the study.
- A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).
- Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit.
- Refusal of or inability to tolerate compression therapy.
- Therapy of the target ulcer with autologous skin graft, Apligraf™, or Dermagraft™ within 30 days preceding the Screening Visit.
- History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers).
- Any prior exposure to HP802-247 or its vehicle.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01656889

United States, Arizona | |
Glendale, Arizona, United States, 85306 | |
Phoenix, Arizona, United States, 85006 | |
Phoenix, Arizona, United States, 85012 | |
Tucson, Arizona, United States, 85723 | |
Tucson, Arizona, United States, 85724 | |
United States, California | |
Carlsbad, California, United States, 92009 | |
Castro Valley, California, United States, 94546 | |
Fresno, California, United States, 93720 | |
Laguna Hills, California, United States, 92653 | |
Long Beach, California, United States, 90822 | |
Los Angeles, California, United States, 90095 | |
San Diego, California, United States, 92013 | |
San Francisco, California, United States, 94115 | |
Stockton, California, United States, 95204 | |
Sylmar, California, United States, 91342 | |
United States, District of Columbia | |
Washington, District of Columbia, United States, 20007 | |
United States, Florida | |
Gainesville, Florida, United States, 32605 | |
Hialeah, Florida, United States, 33013 | |
Miami, Florida, United States, 33125 | |
South Miami, Florida, United States, 33143 | |
Tamarac, Florida, United States, 33321 | |
United States, Illinois | |
Chicago, Illinois, United States, 60611 | |
Chicago, Illinois, United States, 60612 | |
Chicago, Illinois, United States, 60616 | |
Jacksonville, Illinois, United States, 62650 | |
North Chicago, Illinois, United States, 60064 | |
Springfield, Illinois, United States, 62702 | |
United States, Maryland | |
Baltimore, Maryland, United States, 21224 | |
United States, Massachusetts | |
Boston, Massachusetts, United States, 02118 | |
Cambridge, Massachusetts, United States, 02138 | |
United States, Nevada | |
Las Vegas, Nevada, United States, 89119 | |
United States, New Jersey | |
Emerson, New Jersey, United States, 07630 | |
United States, New York | |
New York, New York, United States, 10025 | |
United States, North Carolina | |
Chapel Hill, North Carolina, United States, 27599 | |
United States, Ohio | |
Akron, Ohio, United States, 44307 | |
United States, Oklahoma | |
Tulsa, Oklahoma, United States, 74127 | |
United States, Pennsylvania | |
Dunmore, Pennsylvania, United States, 18512 | |
Wyomissing, Pennsylvania, United States, 19610 | |
United States, Texas | |
Dallas, Texas, United States, 75390 | |
Fort Worth, Texas, United States, 76104 | |
Fort Worth, Texas, United States, 76107 | |
San Antonio, Texas, United States, 78229 | |
United States, Utah | |
St. George, Utah, United States, 84770 | |
United States, Virginia | |
Roanoke, Virginia, United States, 24013 | |
United States, Washington | |
Tacoma, Washington, United States, 98431 | |
Canada, British Columbia | |
Vancovuer, British Columbia, Canada, V5Z1M9 | |
Canada, Ontario | |
Hamilton, Ontario, Canada, L8R2R3 | |
London, Ontario, Canada, N6C5J1 | |
Sudbury, Ontario, Canada, P3E5J1 | |
Canada, Quebec | |
Sherbrooke, Quebec, Canada, J1H5N4 |
Study Chair: | Herbert B Slade, MD | Chief Medical Officer | |
Study Director: | Tommy Lee, MSHS | Associate Director Clinical Operations | |
Principal Investigator: | Robert Kirsner, MD | Investigator | |
Principal Investigator: | William Marston, MD | Investigator |
Responsible Party: | Healthpoint |
ClinicalTrials.gov Identifier: | NCT01656889 History of Changes |
Other Study ID Numbers: |
802-247-09-029 |
First Posted: | August 3, 2012 Key Record Dates |
Results First Posted: | March 14, 2016 |
Last Update Posted: | March 14, 2016 |
Last Verified: | February 2016 |
Keywords provided by Healthpoint:
Venous leg ulcer ulcer venous stasis compression |
venous venous stasis ulcer vlu |
Additional relevant MeSH terms:
Ulcer Leg Ulcer Varicose Ulcer Pathologic Processes Skin Ulcer Skin Diseases Varicose Veins |
Vascular Diseases Cardiovascular Diseases Pharmaceutical Solutions Thrombin Hemostatics Coagulants |